These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10587294)

  • 1. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
    Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
    Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGI 114: augmentation of antitumor activity when combined with topotecan.
    Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
    J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
    Hidalgo M; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
    Anticancer Drugs; 1999 Mar; 10(3):295-302. PubMed ID: 10327036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
    MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
    Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
    Kelner MJ; McMorris TC; Estes L; Wang W; Samson KM; Taetle R
    Invest New Drugs; 1996; 14(2):161-7. PubMed ID: 8913837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of oxaliplatin against human tumor colony-forming units.
    Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
    Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
    Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
    Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft.
    Kelner MJ; McMorris TC; Estes L; Samson KM; Bagnell RD; Taetle R
    Eur J Cancer; 1998 May; 34(6):908-13. PubMed ID: 9797706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
    van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
    Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
    Hammond LA; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Eur J Cancer; 2000 Dec; 36(18):2430-6. PubMed ID: 11094320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.
    Kelner MJ; McMorris TC; Estes LA; Oval MY; Rojas RJ; Lynn JR; Lanham KA; Samson KM
    Anticancer Drugs; 2000 Mar; 11(3):217-24. PubMed ID: 10831281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.
    Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
    Cancer Chemother Pharmacol; 1999; 44(3):235-40. PubMed ID: 10453725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours.
    Sato Y; Kashimoto S; MacDonald JR; Nakano K
    Eur J Cancer; 2001 Jul; 37(11):1419-28. PubMed ID: 11435075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
    Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
    Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
    Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antidotes for extravasation injury produced by 6-hydroxymethylacylfulvene (MGI 114), a novel cytotoxic antitumor agent, in an intradermal toxicity model in rats.
    Marshall RF; Arthaud LE; MacDonald JR
    Cancer Chemother Pharmacol; 2000; 45(5):397-401. PubMed ID: 10803923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of temozolomide against human tumor colony-forming units.
    Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
    Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol.
    McMorris TC; Elayadi AN; Yu J; Hu Y; Kelner MJ
    Drug Metab Dispos; 1999 Sep; 27(9):983-5. PubMed ID: 10460795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.
    McMorris TC
    Bioorg Med Chem; 1999 May; 7(5):881-6. PubMed ID: 10400341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.